A line of tumor-infiltrating lymphocytes (660TIL) specifically lysed the autologous HLA-A2 ⍣ melanoma (660MEL) and also most A2 ⍣ melanoma cell lines. We immunoprecipitated A2 from a large number (>10 12 ) of 660MEL cells, extracted naturally processed peptides, fractionated them by HPLC, screened the fractions for recognition by 660TIL, and found a single predominant and a minor peak of activity. Although too little was recovered of the major 660MEL peptide to establish its sequence, HPLC fingerprinting showed that it did not correspond to any of the known A2-associated melanoma peptides recognized by T cells, including peptides from tyrosinase, MART-1/Melan-A, gp100 and MAGE-3. The major 660MEL antigenic peptide appears to be derived from MART-1/Melan-A but is neither AAGIGILTV nor ILTVILGVL nor any other MART-1/Melan-A peptide containing the A2 consensus motif. The multiplicity of melanoma peptides recognized by CD8 ⍣ T cells, most of which are non-mutated (including most likely the present 660MEL peptide), suggests the existence of unknown mechanisms, perhaps similar to those operating in autoimmune disorders, whereby T cells that recognize normal 'self' sequences become activated.
Introduction
In the 1980s, cytotoxic T lymphocytes (CTL) reactive against (e.g. see below, Table 2 ). Currently, trials are in progress to assess whether peptide-induced, tumor-specific immune autologous melanomas were isolated from patients' peripheral blood, lymph nodes and tumor tissues. Some of these CTL responses can have significant effects on tumor progression and on survival (8) (9) (10) . were shown to recognize allogeneic as well as autologous melanomas, provided the melanomas used as target cells Much progress has been made in the identification of naturally processed peptide antigens recognized by specific expressed the same class I MHC (MHC-1) molecule, implying the existence of key antigens shared among melanomas from CTL in a variety of systems, including viral infection, allogeneic responses and melanoma, but it is not clear why in certain different patients (1) (2) (3) (4) (5) . Following the discovery that T cell antigens consist of short peptides non-covalently bound to instances (such as influenza virus infection), T cells are effective in ridding the host of unwanted target cells, while MHC-I molecules (6) , it became possible to look for the peptides present on melanoma cell surfaces that are recogin other cases (notably HIV infection and many cancers), abundant and vigorous T cell responses can readily be nized by melanoma-reactive T cells. As of the early 1990s, no such peptides had been identified (7) ; since then there demonstrated but apparently are insufficient to eradicate target cells. Some factors thought to limit T cell-target cell has been an explosion of information regarding the identities of T cell antigens on melanoma cells and a few other cancers reactions include: poor MHC expression, absence of appro-priate accessory molecules, antigen escape mutations and served fresh tumor and was maintained in monolayer culture using DME supplemented with 10% heat-inactivated fetal low TCR affinity for peptide-MHC ligands. Another critical parameter in regulating target cell lysis by CTL in vivo may bovine serum (FBS), 500 U/ml penicillin, 50 µg/ml streptomycin, 2 mM L-glutamine and 10 mM HEPES, pH 7.3. 660MEL be the density of specific antigens (i.e. naturally processed peptide-MHC-I complexes) on target cell surfaces (11, 12) .
cells were adapted to growth in 850 cm 2 roller bottles for large-scale culture and were harvested by treatment with 5 The number of these complexes per target cell may often be below the threshold required for efficient lysis in vivo by mM EDTA, pH 8.0, followed by centrifugation. Melanoma cell lines NA8, NA8-Aa and NA8-tyrosinase [from Drs Aline Van Pel existing CTL specific for that antigen. Because CTL activity is usually studied in vitro using somewhat arbitrary concentraand Thierry Boon (23) ], F0-1/neo and F0-1/A2 [from Dr Richard A. Zeff (24) ], SK-MEL-30, SK-MEL-37, SK-MEL-64, SK-MELtions of synthetic peptides and high numbers of T cells in standardized cytotoxicity assays, information about the den-75, SK-MEL-113, SK-MEL-119, SK-MEL-133 and WM88 (from Drs Alan Buckler and Nic Dracopoli), and SK-MEL-5, SKsity of a naturally processed peptide antigen and how it compares to the density of ligand required for T cell lysis MEL-28, HT-144 and Malme-3M (purchased from ATCC, Rockville, MD) were maintained similarly to 660MEL, with the in vivo is usually non-existent. Thus a first step in addressing the potential role of ligand density in T cell reactions is to addition of 1 mg/ml G418 (Gibco/BRL) for transfected cell lines NA8-Aa, NA8-tyrosinase, F0-1/neo and F0-1/A2. JY determine the identities and natural abundances of various peptide antigens recognized by T cells.
target cells are A*0201 ϩ Epstein-Barr virus-transformed B cells, and T2 are A*0201 ϩ antigen-processing mutant TϫB We describe here our characterization of the peptide(s) involved in recognition and lysis of a melanoma cell line, cell hybrids (from Dr Peter Cresswell). 660MEL, by an autologous CD8 ϩ tumor-infiltrating lymphocyte Peptide synthesis and chromatography (TIL) line (660TIL), using biochemical methods similar to those which led to the successful identification of naturally Peptides were synthesized by standard t-Boc chemistry on an Applied Biosystems Model 430A, analyzed by reverse processed viral (13,14) and allogeneic (15) (16) (17) peptides. Despite the use of an enormous number of cultured melanoma phase HPLC and amino acid analysis, and found to be Ͼ90% pure. Several peptides derived from the MART-1 sequence cells (Ͼ10 12 ), we were unable to determine a particular peptide sequence, underscoring the limitations of direct biowere kindly provided by Drs Yutaka Kawakami and Steven A. Rosenberg (25) . A characteristic HPLC profile ('chromatochemical approaches to the isolation of antigenic peptides when their natural abundance is very low. However, we found graphic signature') was determined for each synthetic peptide by recording the retention time of~1 µg peptide under three that: (i) the major 660MEL peptide is different from all other published antigenic melanoma peptides by chromatographic or four rigidly defined HPLC conditions (column, solvents, gradient and flow rate). HPLC conditions were as follows: (A) criteria; (ii) the natural abundance of the predominant peptide is extremely low (Ͻ50 copies per melanoma cell); (iii) the C18 column (Vydac 218TP104), solvent A ϭ 0.1% trifluoroacetic acid (TFA; Pierce, Rockford, IL) in H 2 O, solvent 660MEL peptide appears to be encoded by MART-1/Melan-A (18, 19) ; (iv) the major 660MEL peptide lacks the commonly B ϭ 0.085% TFA in acetonitrile (J. T. Baker) ('TFA system'), gradient ϭ 1.0% B/min, flow rate ϭ 1.0 ml/min; (B) phenyl used consensus motif for A2-associated natural peptides (20) ; and (v) like most known peptides recognized by anticolumn (Vydac 219TP54), TFA system, gradient ϭ 0.5% B/ min, flow rate ϭ 1.0 ml/min; (C) C4 column (Vydac 214TP54), tumor T cells, the major 660MEL peptide seems to be a 'self' rather than a mutated peptide, drawing attention to the TFA system, gradient ϭ 0.25% B/min, flow rate ϭ 1.0 ml/min; and (D) pH stable polymeric column (ymc 2ϫ250 mm), solvent autoimmune nature of the CTL response to melanoma cells.
A ϭ 125 mM triethylamine acetate (Applied Biosystems, Foster City, CA) in H 2 O, pH 7.1, solvent B ϭ 75 mM triethylamine Methods acetate in acetonitrile, gradient ϭ 0.15% B/min, flow rate ϭ 0.25 ml/min. HPLC retention times of synthetic peptides were Cell lines confirmed by repeat injections and were reproducible to within 1 min for a particular peptide and chromatographic Cell line 660TIL was established from cryopreserved fresh 660MEL tumor samples provided by Dr Steven A. Rosenberg condition. and was maintained as previously described (21,22) using Isolation and TFA elution of peptide-HLA-A2 complexes serum-free AIM V medium (Gibco/BRL, Gaithersburg, MD), 1000 U/ml rIL-2, 500 U/ml penicillin, 50 µg/ml streptomycin, Batches of 10 9 -10 10 melanoma cells were pelleted and lysed in hypotonic medium at 4°C (27); all subsequent steps were 250 µg/ml amphotericin B and 2 mM L-glutamine. 660TIL was stimulated with autologous 660MEL cells at intervals of 2-3 performed at 4°C in the presence of 100 µM phenylmethylsulfonyl fluoride, 200 µM dithiothreitol and 0.02% NaN 3 . Memweeks and retained anti-tumor CTL activity in standardized cytotoxicity assays for at least several months (Ͼ50% specific branes were collected by ultracentrifugation for 60 min at 105,000 g, solubilized in 3-4% Brij 58 (Pierce) and passed lysis at a CTL:target cell ratio of 50:1), after which cryopreserved 660TIL cells were thawed and maintained in the same over a set of four immunoaffinity columns arranged in series as follows: Sepharose only, pooled mouse γ-globulin coupled way. The 660TIL phenotype was CD3 ϩ CD8 ϩ HLA-A2 ϩ , and lysis of 660MEL by 660TIL was blocked by mAb OKT3 and to Sepharose, mAb PA2.1 (anti-A2) coupled to Sepharose and mAb W6/32 (anti-MHC-I) coupled to Sepharose. After OKT8, mAb against ICAM and LFA-1, mAb PA2.6, BB7.2 and PA2.1 against A2, but not by mAb BB7.1 against HLA-B7 (22).
being washed with at least 30 column volumes of buffers, each column was eluted with 50 mM diethylamine-HCl, pH Melanoma cell line 660MEL was established from cryopre-11, 0.2% Brij 58. A2 purity was assessed by SDS-PAGE as a tracer in order to ensure complete TFA elution of endogenous peptides from purified peptide-A2 complexes a Numbers in parentheses are mean fluorescence values in flow cytometric analyses using mAb PA2.1 and FITC-conjugated F(abЈ) 2 (27). In smaller trials, cell pellets were extracted directly with fragment of goat anti-mouse IgG.
TFA, without HLA purification, as previously described (28) .
b Percent specific lysis in cytotoxicity assays at the indicated HPLC conditions for the fractionation of naturally processed CTL:target cell ratios.
peptide extracts were identical to conditions A, B, C and D as described above.
Cytotoxicity assays
Results Cultured melanoma cells to be tested directly as targets for 660TIL recognizes a majority of A2 ϩ melanoma cell lines lysis by 660TIL were labeled with 51 Cr for 1 h at 37°C, washed three times with FBS-containing medium and placed in wells
The cytotoxic activity of 660TIL against a variety of A2 ϩ and A2 -melanoma cell lines was tested, with autologous 660MEL of a 96-well round-bottom plate at 5ϫ10 3 cells/well. For synthetic peptide testing or for screening HPLC fractions of included in each assay as a positive control (Table 1) . Of eight different A2 ϩ lines, seven were lysed to an appreciable naturally processed peptide extracts, the samples were first distributed in 96-well plates, dried overnight and 5ϫ10 3 51 Crextent. Lysis did not correlate linearly with mean levels of A2 expression, e.g. SK-MEL-30 had over a five times higher labeled JY or T2 target cells (both A*0201 ϩ ) were added for 1 h at 37°C. 660TIL were then added at appropriate ratios of mean level of A2 than F0-1/A2 but was lysed more poorly. Of seven A2 -cell lines, one was lysed (though weakly) by CTL:target cells (50:1 unless otherwise noted) for 4 h at 37°C. Percent specific lysis was calculated from the average of 660TIL. Since there is evidence for limited oligoclonality of TIL after many months in culture (32-35), we conclude that duplicates as 100ϫ( 51 Cr release into supernatant -spontaneous release)/(total release in detergent -spontaneous 660TIL recognizes one or more antigens shared by most A2 ϩ melanomas. release). In a few assays, mAb MA2.1 and β 2 -microglobulin were added to T2 cells in an effort to increase the sensitivity A single melanoma peptide mediates most of the A2-restricted of peptide detection as reported previously (29) (30) (31) , but no response of 660TIL increase in specific lysis values was noted. All synthetic peptides and HPLC fractions were also tested for non-specific Figure 1 shows vigorous lysis by 660TIL of JY target cells pulsed with HPLC fractions of A2-bound peptides from 10 10 lysis of target cells in the absence of CTL ('toxicity'). melanoma cells (2.5ϫ10 9 cell equivalents per well). Fractions Flow cytometry 44 , 45 and 46 each gave rise to Ͼ90% specific target cell lysis and likely represent a single active peptide eluting over Cultured melanoma cells were checked to confirm A2 status and to compare mean A2 levels. After cells were washed and 2-3 min, because in comparable experiments (e.g. Fig. 2A ) this activity was largely contained within a single fraction (no. resuspended in PBS containing 5% FBS and 0.01% NaN 3 , 5ϫ10 5 (10 10 ) were lysed hypotonically, membranes were isolated by ultracentrifugation and solubilized with detergent, and solubilized membranes were passed over a set of four immunoaffinity columns as described in Methods. Each column was eluted and the protein fractions were concentrated and treated with TFA to separate bound peptides. Peptides extracted from purified A2 (PA2.1 column), purified non-A2 HLA molecules (W6/32 column) and non-specific Fig. 2 . Purification of the major melanoma antigen recognized by proteins (mouse γ-globulin column) were separately fractionated 660TIL. A2-bound peptides were obtained from 4ϫ10 11 cultured under HPLC condition A. Fractions were collected at 1 min intervals 660MEL cells and fractionated by HPLC as described in Fig. 1 , and tested for sensitizing activity in a standardized cytotoxicity assay except that immunoprecipitation was performed instead of affinity using 660TIL and JY target cells at a CTL:target cell ratio of 50:1.
chromatography. Active fractions were subjected to re-chromatoShown are fractions from the PA2.1 column; fractions derived from graphy under HPLC conditions A, B, C and D as described in the W6/32 and mouse γ-globulin columns lacked significant activity.
Methods, for a total of four serial rounds of chromatography. HPLC The shoulder peak at fraction 42 was observed consistently in different fractions were collected at 0.5 or 1.0 min intervals and 1-2% of each experiments; the small peak at fraction 33 was not always seen.
fraction was tested in standardized cytotoxicity assays using 660TIL and JY or T2 target cells. UV absorbance profiles for each round of chromatography were generally unrevealing, since they did not predict the retention times of biologically active peptides, and are purification and characterization of this minor peptide were not shown.
not undertaken in view of its comparatively marginal biologic activity. The finding of more than two peaks of sensitizing activity among similarly derived HPLC fractions in other studies (36) (37) (38) might be due to a greater degree of polyclonmolecules of peptide were recovered per melanoma cell. While only approximate, these estimates indicate that the ality in the T cell populations used. natural abundance of the major 660MEL peptide is likely to Abundance of the naturally processed 660MEL peptide is be extremely low. quite low
The major 660MEL peptide is not one of the known melanoma After four rounds of HPLC (Fig. 2) , the major 660MEL peptide T cell antigens was judged to be highly purified based on up to 50-fold enrichment at each round. Accordingly, the sample was In order to determine whether the major 660MEL peptide recognized by our 660TIL line was one of the known melanoma subjected to mass spectrometric analysis but a sequence could not be derived due to insufficient material. However, antigens encoded by the tyrosinase, MART-1/Melan-A, gp100/ Pmel17 or MAGE-3 genes and recognized by other A2-we can offer some estimates of natural abundance. We assume an initial peptide yield of 50% from melanoma cell restricted T cells (see Table 2 ), we employed two distinct strategies. First, we synthesized the known melanoma pepextraction and a yield of 50% per HPLC round, values in line with previous studies (12, 17, 39, 40) . Based on the ability tides and tested them for sensitizing activity in cytotoxicity assays with 660TIL. All peptides tested negative; the MARTto detect Ͻ1 pmol of known peptide standards by mass spectrometry, the starting amount of peptide (from 4ϫ10 11 1/Melan-A peptide AAGIGILTV (25) consistently exhibited slight activity over background (10-23% lysis at the extremely cells) would then be Ͻ50 molecules per melanoma cell. An independent estimate of peptide abundance may be high peptide concentration of 100 µM and less at lower concentrations), but this was far below the activity obtained calculated by assuming an SD 50 value of the unknown 660MEL peptide [concentration at which 50% of maximal lysis occurs with HPLC-fractionated natural extracts of the 660MEL peptide (up to 100% specific lysis, Table 3 , and Figs 1 and 2). (27)]. If the SD 50 is 10 pM [comparable to other known naturally processed peptides in assays similar to those used To definitively rule out the known melanoma peptides, we devised a second strategy in which each synthetic peptide here (12, 14, 27, 31, (39) (40) (41) ], and since 1% of the total sample was used in a cytotoxicity assay to give 50% of maximal lysis was characterized chromatographically with the HPLC conditions used to purify the 660MEL peptide (Fig. 2) . By exploiting (i.e. 4ϫ10 9 cell equivalents per 200 µl well), then Ͻ10 a Excluding viral peptides and oncogene-related peptides that were used to stimulate T cells in vitro. b Underlined residues are mutated. Residues in parentheses indicate that both the 9mer and 10mer are recognized to a similar extent by T cells. c SD 50 values (27) are approximate synthetic peptide concentrations at which 50% of maximal lysis occurs in cytotoxicity assays. Methods vary with regard to incubation of target cells with peptide throughout the assay or pulsing target cells with peptide prior to adding CTL. d A peptide is considered to be naturally occurring when it is isolated from natural sources or when the HPLC profile of the synthetic peptide is shown to match that of an active natural fraction.
e Cox et al. (40) reported the isolation of natural peptide YMDGTMSQV (N→D at position 3), later shown to be the product of post-translational cellular deamidation (75) . a Percent specific lysis in cytotoxicity assays with 660TIL and JY or T2 target cells at a CTL:target cell ratio of 50:1. Peptides were tested at final concentrations of 100 (shown) and 10 µg/ml. In each assay a positive control using 660MEL target cells gave at least 50% specific lysis. Some assays were performed using mAb MA2.1 and exogenous β 2 -microglobulin as described (29) (30) (31) , without significantly different results.
b HPLC retention times are shown under three different sets of chromatographic conditions (column, solvents, gradient and flow rate) as described in Methods. ND, not done.
the considerable resolving power of serial rounds of HPLC, any given peptide could be excluded from consideration if its chromatographic signature did not match that of the naturally processed 660MEL peptide. A precise match would be strong evidence of a correctly identified sequence. As shown in Table 3 , none of the known melanoma peptides tested had the highly reproducible (Ϯ1 min) chromatographic signature of the major 660MEL peptide. MART-1/Melan-A peptide AAGIGILTV differed in retention time by 7-8 min from the natural extract under HPLC condition C, effectively ruling out this peptide as the one we had purified. Interestingly, peptide AAGIGILTV eluted in fraction 43 under HPLC condition A, very close to the minor peak of activity we consistently observed in fractions 41-42 of 660MEL extracts (Figs 1 and 
660TIL recognizes a product of the MART-1/Melan-A gene
The MART-1/Melan-A gene was independently identified in [41] [42] or to a different, unknown MART-1/Melan-A peptide (i.e. the major 660MEL peptide present in fractions [44] [45] . If two laboratories as the source of melanoma peptides recognized by both TIL and peripheral blood lymphocytes (PBL) the former is true, then the major 660MEL peptide might not be derived from MART-1/Melan-A, although we consider this (18, 19) and was subsequently found to encode a peptide (AAGIGILTV) recognized in vitro by nine of 10 A2-restricted possibility remote because of the very weak activity of the minor peptide in HPLC fractions 41-42 and the high levels of TIL obtained from 10 melanoma tumors, including TIL derived independently by Kawakami et al. from the 660MEL tumor lysis of Melan-A-transfected NA8 cells (Fig. 3) . It is also conceivable that the 660MEL peptide has a post-translational (25) . To determine whether our 660TIL line recognized a product of the MART-1/Melan-A gene, we relied on cytotoxicity modification (cf. Table 2 , footnote e), rendering its identification more difficult. assays using as targets either an A2 ϩ melanoma cell line (termed NA8) that is not recognized by 660TIL or NA8
The major 660MEL peptide does not possess the A2 transfected with the Melan-A gene (termed NA8-Aa) (23) .
consensus motif NA8 cells transfected with the tyrosinase gene were also tested. Figure 3 shows that our 660TIL recognizes a product On the basis of Table 3 , the major 660MEL peptide was neither of the two MART-1/Melan-A peptides known to be generated only in Melan-A-transfected NA8 cells, indicating that one or more peptides derived from Melan-A is recognized recognized by A2-restricted anti-tumor T cells. Since the other logical candidates for the 660MEL peptide were short by 660TIL. We could not determine whether recognition of NA8-Aa by 660TIL was due to peptide AAGIGILTV (potentially peptides derived from the 118 amino acid sequence encoded by MART-1/Melan-A, we tested all of the MART-1/Melan-A the minor sensitizing 660MEL peptide seen in HPLC fractions a Percent specific lysis in cytotoxicity assays with 660TIL and JY or T2 target cells at a CTL:target cell ratio of 50:1. Peptides were tested at final concentrations of 100 (shown) and 10 µg/ml. In each assay a positive control using 660MEL target cells gave at least 50% specific lysis. Some assays were performed using mAb MA2.1 and exogenous β 2 -microglobulin as described (29) (30) (31) , without significantly different results.
b HPLC retention times are shown under three different sets of chromatographic conditions (column, solvents, gradient and flow rate) as described in Methods. ND, not done. peptides that contained a liberal consensus motif for natural through the use of distinctive chromatographic signatures of naturally processed and synthetic peptides, that the major peptides associated with A2, i.e. nine (or 10) amino acid residues with alanine, isoleucine, leucine, methionine, threonantigenic peptide isolated from 660MEL cells differs from the peptides recognized by other A2-restricted anti-melanoma ine or valine at position 2 and alanine, isoleucine, leucine, methionine or valine at position 9 (or 10) (20) . Because of the T cells (Table 3) . Indeed the considerable diversity of melanoma peptides recognized by A2-restricted T cells is further slight activity of peptide AAGIGILTV in 660TIL assays, we also tested a number of synthetic peptides ranging in length emphasized by the finding that among the peptides not recognized by our 660TIL line are peptide sequences from from nine to 15 amino acids and flanking the known antigenic sequences from MART-1/Melan-A. Altogether we tested 43 MART-1/Melan-A and gp100 that are recognized by an A2-restricted 660TIL line derived independently by Kawakami synthetic peptides that were the most likely candidates from MART-1/Melan-A, using 660TIL cytotoxicity assays and/or the et al. from the same melanoma tumor (660MEL) (25, 42) . In contrast, anti-viral T cells often respond to one predominant chromatographic fingerprinting approach to evaluate these peptides: none of them matched the major 660MEL peptide peptide presented by virus-infected cells (13, 14, 43, 44) . Cells infected by lytic viruses such as influenza, vaccinia, (Tables 3 and 4 , and Fig. 4 ). In addition, we synthesized and tested two peptides from the MAGE-1 sequence that Sendai or VSV produce large numbers of viral peptide-MHC-I complexes, and may be lysed efficiently both in vitro and contained the A2 consensus motif, as well as two peptides from MART-1/Melan-A that had molecular masses of 1301 and in vivo by specific CTL. Tumor cells, however, might resemble cells chronically infected by persistent viruses such as 1007 respectively, because mass spectrometric sequencing efforts had tentatively suggested the presence of peptides of Epstein-Barr virus or HIV, in which low viral protein expression results in low densities of peptide-MHC-I complexes at the these sizes in our purified natural extracts. None of these synthetic peptides matched the naturally processed 660MEL cell surface, perhaps accounting for ineffectual destruction of these target cells. We recently showed that chronically peptide by cytotoxicity assay or by HPLC fingerprinting (Table 4) .
HIV-infected cells contained an average of~12 and~400 copies of two different peptides recognized by human HIVspecific CTL clones, and the infected cells were lysed much Discussion less efficiently by CTL specific for the peptide expressed at the lower level (12) . Little information is available regarding the Ten different peptide sequences from four proteins (tyrosinase, MART-1/Melan-A, gp100 and MAGE-3) have recently abundance of naturally processed peptide-MHC-I complexes on melanoma cells, since only two of the peptides listed in been identified that are recognized by anti-melanoma T cells in association with HLA-A2 (Table 2) . In this study, we analyzed Table 2 that are recognized by human T cells were purified directly from tumor samples. Based on our experience, the the naturally processed peptides recognized by a line of TIL (660TIL) obtained from an A2 ϩ melanoma (660MEL). We show, study of Cox et al. (40) , and the failure of other laboratories The indicated synthetic peptides were tested for sensitizing activity in standardized cytotoxicity assays using 660TIL and JY target cells at a CTL:target cell ratio of 50:1. Peptides were tested at final concentrations of 100 (shown) and 10 µg/ml. As a positive control, 660MEL target cells were included in each assay and gave specific lysis values Ͼ50-60%. Peptides enclosed in boxes are known melanoma peptides recognized by A2-restricted TIL in other laboratories (25, 31) . ND, not done.
to report the biochemical isolation of tumor peptides, we anti-melanoma T cells stands in contrast to the decades-old expectation that tumor-associated protein antigens in general suspect that the densities of tumor peptide-MHC-I complexes may in general be quite low. An apparent exception is are aberrations, i.e. mutated proteins or proteins normally found primarily in the fetal state [so-called oncofetal antigens found in the mouse Lewis lung carcinoma, where a naturally processed tumor antigen is one of the more abundant MHC-(46)]. As noted previously (47, 48) , the 'self' nature of antigens recognized by anti-melanoma T cells suggests an analogy I-associated peptides (45) . Low ligand densities do not necessarily imply poor killing by CTL; even extremely small numbers with autoimmune T cell responses. How good is this analogy? Self-reactive T cells responsible of peptide-MHC-I complexes may elicit vigorous CTL responses, depending on the affinity of TCR for these ligands for autoimmune disorders such as diabetes have been analyzed using the concept of checkpoints, with disease states as well as other factors (12, 26) .
A further striking feature emerging about melanoma antirequiring the progression of self-reactive T cells through several stages (49) . T cells that can recognize self antigens gens recognized by T cells is that they predominantly have normal 'self' (i.e. non-mutated) sequences (Table 2 ). The can be isolated from healthy individuals without detectable immunopathology (49) (50) (51) . Recent studies similarly indicate peptide studied here is also likely to be non-mutated, since 660TIL specifically lysed A2 ϩ target cells (NA8) transfected the existence of MART-1/Melan-A-specific T cells in healthy individuals who have no evidence of autoreactivity against with the Melan-A gene, which has no known mutation (Fig.  3) . The multiplicity of antigenic peptides that are derived from normal melanocytes (such as vitiligo) (52, 53) . When selfreactive T cells are activated to the next stage, they extensively non-mutated proteins in melanoma cells and recognized by infiltrate antigenic sites but do not cause target cell destrucHowever, these approaches serve to identify a gene, not an antigenic peptide. In order to determine what peptide tion. This situation, exemplified by lymphocytic infiltration in the pancreatic β-islets of male non-obese diabetic mice and sequences are recognized, the deduced gene products must be scanned for candidate sequences, usually based on in a TCR transgenic mouse model (49) , may be analogous to the presence of anti-melanoma T cells in melanoma tumors empiric consensus motifs (20) . Synthetic peptides are then tested in cytotoxicity assays, often requiring high concentrathat continue to grow. Finally, in full-blown autoimmune disease the infiltrating T cells bring about destruction of the target tions (up to µM, see Table 2 ) to demonstrate sensitizing activity, unlike the few known naturally processed tumor organ. This stage, pathological in the case of autoimmune disease, is desirable when the target 'self' organ is a tumor; peptides, which are active at pM concentrations. Wallny et al. took a useful further step for one of the (mouse) tumor however, while Rosenberg et al. have had some success in using TIL for immunotherapy in patients with metastatic peptides that had been defined at the synthetic peptide level and verified its presence in tumor extracts by HPLC criteria melanoma (54) , this stage seems not to be achieved spontaneously in most clinically detectable human melanomas.
(41); to our knowledge this has not yet been done for any of the human tumor peptides. It should now be possible to It is possible that the ability of anti-melanoma T cells to mediate tumor cell destruction is overestimated by the determine how many of the currently defined melanoma antigens (Table 2) are present on tumor cell surfaces in inescapably artificial nature of in vitro cytotoxicity assays, in which CTL stimulated with high doses of IL-2 are added in quantities sufficient to elicit a CTL response. In principle, tumor specimens and various normal tissues (e.g. melanogreat excess over target cells (e.g. 50:1) in a U-bottom well for several hours. While useful as assays, these conditions cytes, retinal cells) as well as cultured tumor cell lines should all be amenable to screening for the presence of known probably bear little resemblance to what obtains in a typical tumor, particularly when synthetic peptides are also added antigenic peptides by chromatographic approaches such as those described here. to the assays at massively supra-physiological levels: at 10 µM a peptide that binds to an MHC-I protein on a target cell tions suggest that antigen-specific T cell responses can be stimulated to destroy normal melanocytes, and that these T cells might also be stimulated to kill melanoma tumor cells.
Abbreviations Whether such T cell activation may best be achieved by the It is important to emphasize that the sequence of the melanoma peptide we studied could not be established References despite our having used Ͼ10 12 cultured tumor cells (harvested
